MENU
LXRX
AS OF
Feb 4, 04:59 PM (EDT)
Price
$1.29
Change
+$0.01 (+0.78%)
Capitalization
532.78M
42 days until earnings call
Intraday BUY SELL Signals
+Compare
LXRX
Stock ticker: NASDAQ
AS OF
Feb 4, 04:59 PM (EDT)
Price
$1.29
Change
+$0.01 (+0.78%)
Capitalization
532.78M

LXRX Lexicon Pharmaceuticals Forecast, Technical & Fundamental Analysis

Lexicon Pharmaceuticals Inc is a biopharmaceutical company... Show more

Industry: #Biotechnology
LXRX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for LXRX with price predictions
Feb 03, 2026

LXRX's RSI Oscillator recovers from overbought zone

The 10-day RSI Indicator for LXRX moved out of overbought territory on January 28, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 instances where the indicator moved out of the overbought zone. In of the 31 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on January 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LXRX as a result. In of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for LXRX turned negative on January 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .

LXRX moved below its 50-day moving average on January 30, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LXRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

LXRX broke above its upper Bollinger Band on January 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for LXRX entered a downward trend on January 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The 10-day moving average for LXRX crossed bullishly above the 50-day moving average on January 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where LXRX advanced for three days, in of 219 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LXRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.435) is normal, around the industry mean (27.519). P/E Ratio (0.000) is within average values for comparable stocks, (51.491). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.893). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (6.523) is also within normal values, averaging (331.843).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LXRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
LXRX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

LXRX is expected to report earnings to rise 67.50% to -6 cents per share on March 18

Lexicon Pharmaceuticals LXRX Stock Earnings Reports
Q4'25
Est.
$-0.07
Q3'25
Beat
by $0.03
Q2'25
Beat
by $0.10
Q1'25
Beat
by $0.05
Q4'24
Beat
by $0.03
The last earnings report on November 06 showed earnings per share of -3 cents, beating the estimate of -7 cents. With 436.16K shares outstanding, the current market capitalization sits at 532.78M.
A.I. Advisor
published General Information

General Information

a company, which engages in discovery and development of breakthrough treatments for human disease

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
2445 Technology Forest Boulevard
Phone
+1 281 863-3000
Employees
285
Web
https://www.lexpharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYKCX92.491.08
+1.18%
Rydex Banking C
FGRCX30.85N/A
N/A
Fidelity Advisor Mega Cap Stock C
MXJVX10.89N/A
N/A
Empower International Value Instl
WFEIX59.18-0.57
-0.95%
Allspring Mid Cap Growth Fund - Cl Inst
ADNAX19.62-0.26
-1.31%
American Beacon ARK Transfmt Innov A

LXRX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, LXRX has been loosely correlated with PLRX. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if LXRX jumps, then PLRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LXRX
1D Price
Change %
LXRX100%
+2.40%
PLRX - LXRX
41%
Loosely correlated
+1.68%
VCYT - LXRX
37%
Loosely correlated
-1.10%
DNLI - LXRX
36%
Loosely correlated
-4.22%
FTRE - LXRX
35%
Loosely correlated
-3.62%
NKTX - LXRX
34%
Loosely correlated
+2.78%
More